Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
Portfolio Pulse from Lisa Levin
The article lists the top 5 overbought health care stocks that could negatively impact portfolios this quarter, including Outlook Therapeutics, MorphoSys AG, Krystal Biotech, IDEAYA Biosciences, and Biohaven Ltd. These stocks have high RSI values, indicating they may be overvalued.
June 06, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biohaven Ltd. has a high RSI value of 78.88, indicating it may be overvalued. The stock fell 0.3% to settle at $21.65 on Monday.
Biohaven Ltd. has a high RSI value, which is a momentum indicator that compares a stock's strength on days when prices go up to its strength on days when prices go down. A high RSI value indicates that the stock may be overvalued and could experience a short-term decline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
IDEAYA Biosciences has a high RSI value of 70.85, indicating it may be overvalued. The stock fell 1.9% to close at $24.39 on Monday.
IDEAYA Biosciences has a high RSI value, which is a momentum indicator that compares a stock's strength on days when prices go up to its strength on days when prices go down. A high RSI value indicates that the stock may be overvalued and could experience a short-term decline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Krystal Biotech has a high RSI value of 72.89, indicating it may be overvalued. The stock fell 1.9% to close at $121.79 on Monday.
Krystal Biotech has a high RSI value, which is a momentum indicator that compares a stock's strength on days when prices go up to its strength on days when prices go down. A high RSI value indicates that the stock may be overvalued and could experience a short-term decline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
MorphoSys AG has a high RSI value of 74.05, indicating it may be overvalued. The stock rose 2.6% to close at $6.75 on Monday.
MorphoSys AG has a high RSI value, which is a momentum indicator that compares a stock's strength on days when prices go up to its strength on days when prices go down. A high RSI value indicates that the stock may be overvalued and could experience a short-term decline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Outlook Therapeutics has a high RSI value of 74.33, indicating it may be overvalued. The stock rose 9% to close at $1.75 on Monday.
Outlook Therapeutics has a high RSI value, which is a momentum indicator that compares a stock's strength on days when prices go up to its strength on days when prices go down. A high RSI value indicates that the stock may be overvalued and could experience a short-term decline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100